Infrequent mutation of the p16/MTS1 gene and overexpression of cyclin- dependent kinase 4 in human primary soft-tissue sarcoma

Clinical Cancer Research

Volumn 4, Issue 4, 1998, Pages 1065-1070

  Yao, Jun ^a   Pollock, Raphael E ^a   Lang, Aiqing ^a   Tan, Ming ^a   Pisters, Peter W T ^a   Goodrich, David ^a   El Naggar, Adel ^a   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE; DNA; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ARTICLE; CONTROLLED STUDY; GENE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOFT TISSUE SARCOMA; SOUTHERN BLOTTING; TUMOR GROWTH;

ANIMALS; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P16; CYCLIN-DEPENDENT KINASES; GENES, P16; HUMANS; MICE; MICE, KNOCKOUT; MUTATION; NEOPLASM PROTEINS; PROTO-ONCOGENE PROTEINS; RETINOBLASTOMA PROTEIN; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 0031897448     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (31)

1. Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., and Skolnick, M. H. A cell cycle regulator potentially involved in genesis of many tumor types. Science (Washington DC), 264: 436-440, 1994.
2. Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., and Carson, D. A. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (Lond.), 384: 753-756, 1994.
3. Ohnishi, H., Kawamura, M., Ida, K., Sheng, X. M., Hanada, R., Nobori, T., Yamamori, S., and Hayashi, Y. Homozygous deletions of p16/MTS1 gene are frequent but mutations are infrequent in childhood T-cell acute lymphoblastic leukemia. Blood, 86: 1269-1275, 1995.
4. Giani, C., and Finocchiaro, G. Mutation rate of the CDKN2 gene in malignant gliomas. Cancer Res., 54: 6338-6339, 1994.
5. Shapiro, G. I., Edwards, C. D., Kobzik, L., Godleski, J., Richards, W., Sugarbaker, D. J., and Rollins, B. J. Reciprocal Rb inactivation and p16INK4 expression in primary lung cancers and cell lines. Cancer Res., 55: 505-509, 1995.
6. Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P. A., Ally, D. S., Sheahan, M. D., Clark, W. H. J., Tucker, M. A., and Dracopoli, N. C. Germline p16 mutations in familial melanoma. Nat. Genet., 8: 15-21, 1994.
7. Igaki, H., Sasaki, H., Tachimori, Y., Kato, H., Watanabe, H., Kimura, T., Harada, Y., Sugimura, T., and Terada, M. Mutation frequency of the p16/CDKN2 gene in primary cancers in the upper digestive tract. Cancer Res., 55: 3421-3423, 1995.
8. Yoshida, S., Todoroki, T., Ichikawa, Y., Hanai, S., Suzuki, H., Hori, M., Fukao, K., Miwa, M., and Uchida, K. Mutations of p16Ink4/CDKN2 and p15Ink4B/MTS2 genes in biliary tract cancers. Cancer Res., 55: 2756-2760, 1995.
9. Herman, J. G., Merlo, A., Mao, L., Lapidus, R. G., Issa, J. P., Davidson, N. E., Sidransky, D., and Baylin, S. B. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res., 55: 4525-4530, 1995.
10. Merlo, A., Herman, J. G., Mao, L., Lee, D. J., Gabrielson, E., Burger, P. C., Baylin, S. B., and Sidransky, D. 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/ CDKN2/MTS1 in human cancers. Nat. Med., 1: 686-692, 1995.
11. Spruck, C. H., III, Gonzalez-Zulueta, M., Shibata, A., Simoneau, A. R., Lin, M. F., Gonzales, F., Tsai, Y. C., and Jones, P. A. p16 gene in uncultured tumors. Nature (Lond.), 370: 183-184, 1994.
12. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54: 6078-6082, 1994.
13. Yeager, T., Stadler, W., Belair, C., Puthenveettil, J., Olopade, O., and Reznikoff, C. Increased p16 levels correlate with pRb alterations in human urothelial cells. Cancer Res., 55: 493-497, 1995.
14. He, J., Allen, J. R., Collins, V. P., Allalunis-Turner, M. J., Godbout, R., Day, R. S., and James, C. D. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. Cancer Res., 54: 5804-5807, 1994.
15. Bartkova, J., Lukas, J., Muller, H., Strauss, M., Gusterson, B., and Bartek, J. Abnormal patterns of D-type cyclin expression and G1 regulation in human head and neck cancer. Cancer Res., 55: 949-956, 1995.
16. Serrano, M., Lee, H. W., Chin, L., Cordon-Cardo, C., Beach, D., and DePinho, R. A. Role of the INK4a locus in tumor suppression and cell mortality. Cell, 85: 27-37, 1996.
17. Weinberg, R. A. The retinoblastoma protein and cell cycle control. Cell, 81: 323-330, 1995.
18. Peters, G. The D-type cyclins and their role in tumorigenesis. J. Cell Sci., 18 (Suppl.): 89-96, 1994.
19. Khatib, Z. A., Matsushime, H., Valentine, M., Shapiro, D. N., Sherr, C. J., and Look, A. T. Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas. Cancer Res., 53: 5535-5541, 1993.
20. Maelandsmo, G. M., Berner, J. M., Florenes, V. A., Forus, A., Hovig, E., Fodstad, O., and Myklebost, O. Homozygous deletion frequency and expression levels of the CDKN2 gene in human sarcomas-relationship to amplification and mRNA levels of CDK4 and CCND1. Br. J. Cancer, 72: 393-398, 1995.
21. He, J., Olson, J. J., and James, C. D. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. Cancer Res., 55: 4833-4836, 1995.
22. Schmidt, E. E., Ichimura, K., Reifenberger, G., and Collins, V. P. CDKN2 (p16/MTS1) gene deletion or CDK4 amplification occurs in the majority of glioblastomas. Cancer Res., 54: 6321-6324, 1994.
23. Shan, B., Chang, C. Y., Jones, D., and Lee, W. H. The transcription factor E2F-1 mediates the autoregulation of RB gene expression. Mol. Cell. Biol., 14: 299-309, 1994.
24. Geradts, J., Kratzke, R. A., Niehans, G. A., and Lincoln, C. E. Immunohistochemical detection of the cyclin-dependent kinase inhibitor 2/multiple tumor suppressor gene 1 (CDKN2/MTS1) product p16INK4A in archival human solid tumors: correlation with retinoblastoma protein expression. Cancer Res., 55: 6006-6011, 1995.
25. Gonzalez-Zulueta, M., Bender, C. M., Yang, A. S., Nguyen, T., Beart, R. W., Van Tornout, J. M., and Jones, P. A. Methylation of the 5′ CpG island of the p16/CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res., 55: 4531-4535, 1995.
26. Lukas, J., Aagaard, L., Strauss, M., and Bartek, J. Oncogenic aberrations of p16INK4/CDKN2 and cyclin D1 cooperate to deregulate G1 control. Cancer Res., 55: 4818-4823, 1995.
27. Li, Y., Nichols, M. A., Shay, J. W., and Xiong, Y. Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb. Cancer Res., 54: 6078-6082, 1994.
28. Stepanova, L., Leng, X., Parker, S. B., Harper, J. W. Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev., 10: 1491-1502, 1996.
29. Shigemasa, K., Hu, C., West, C. M., Clarke, J., Parham, G. P., Parmley, T. H., Korourian, S., Baker, V. V., and O'Brien, T. J. p16 overexpression: a potential early indicator of transformation in ovarian carcinoma. J. Soc. Gynecol. Invest., 4: 95-102, 1997.
30. Ikeda, K., Monden, T., Tsujie, M., Izawa, H., Yamamoto, H., Ohnishi, T., Ohue, M., Sekimoto, M., Tomita, N., and Monden, M. Cyclin D, CDK4, and p16 expression in colorectal cancer. Jpn. J. Clin. Med., 54: 1054-1059, 1996.
31. Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., and Lowe, S. W. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell, 88: 593-602, 1997.